Baseline variables associated with GP1111 treatment withdrawal, performed in all switch patients (n=1605) and stratified by diagnosis
| Univariate | Age-adjusted and gender-adjusted | Fully adjusted* | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Rheumatoid arthritis, n=685 | ||||||
| Female gender | 0.85 (0.58 to 1.26) | 0.42 | – | 0.74 (0.48 to 1.14) | 0.17 | |
| Age, years | 1.00 (0.99 to 1.01) | 0.92 | – | 1.01 (0.99 to 1.02) | 0.50 | |
| Previous originator infliximab experienced (yes) | 0.48 (0.29 to 0.77) | 0.002 | 0.46 (0.28 to 0.76) | 0.002 | 0.36 (0.19 to 0.68) | 0.001 |
| Methotrexate use, yes | 0.46 (0.31 to 0.67) | <0.001 | 0.45 (0.31 to 0.66) | <0.001 | 0.60 (0.39 to 0.93) | 0.02 |
| Comorbidities ≥1 | 1.06 (0.73 to 1.54) | 0.75 | 1.05 (0.73 to 1.53) | 0.78 | 0.92 (0.60 to 1.42) | 0.71 |
| CRP, mg/L | 1.01 (1.00 to 1.02) | 0.01 | 1.01 (1.00 to 1.02) | 0.01 | 1.00 (0.99 to 1.01) | 0.59 |
| Patient global VAS, mm | 1.02 (1.01 to 1.03) | <0.001 | 1.02 (1.01 to 1.03) | <0.001 | 1.02 (1.01 to 1.02) | <0.001 |
| In DAS28 remission (yes) | 0.38 (0.25 to 0.58) | <0.001 | 0.36 (0.24 to 0.56) | <0.001 | – | – |
| In CDAI remission (yes) | 0.78 (0.51 to 1.19) | 0.24 | 0.78 (0.51 to 1.19) | 0.25 | – | – |
| DAS28 | 1.67 (1.43 to 1.95) | <0.001 | 1.70 (1.45 to 1.98) | <0.001 | – | – |
| CDAI | 1.06 (1.04 to 1.09) | <0.001 | 1.07 (1.04 to 1.09) | <0.001 | – | – |
| Psoriatic arthritis, n=314 | ||||||
| Female gender | 0.88 (0.51 to 1.51) | 0.64 | – | – | 0.71 (0.39 to 1.31) | 0.28 |
| Age, years | 1.01 (0.99 to 1.03) | 0.42 | – | – | 1.01 (0.99 to 1.04) | 0.40 |
| Previous originator infliximab experienced (yes) | 0.19 (0.06 to 0.62) | 0.006 | 0.17 (0.05 to 0.54) | 0.002 | 0.23 (0.07 to 0.75) | 0.01 |
| Methotrexate use, yes | 1.27 (0.72 to 2.23) | 0.40 | 1.22 (0.68 to 2.18) | 0.51 | 1.27 (0.66 to 2.44) | 0.46 |
| Comorbidities ≥1 | 1.52 (0.88 to 2.62) | 0.14 | 1.53 (0.87 to 2.68) | 0.14 | 1.06 (0.56 to 1.99) | 0.86 |
| CRP, mg/L | 1.01 (1.00 to 1.03) | 0.08 | 1.02 (1.00 to 1.03) | 0.08 | 1.01 (0.99 to 1.03) | 0.40 |
| Patient global VAS, mm | 1.02 (1.01 to 1.03) | <0.001 | 1.02 (1.01 to 1.03) | <0.001 | 1.02 (1.00 to 1.03) | 0.004 |
| In DAS28 remission (yes) | 0.40 (0.22 to 0.74) | 0.003 | 0.37 (0.20 to 0.68) | 0.001 | – | – |
| In CDAI remission (yes) | 1.03 (0.55 to 1.92) | 0.93 | 1.06 (0.56 to 2.01) | 0.86 | – | – |
| DAS28 | 1.64 (1.27 to 2.13) | <0.001 | 1.72 (1.31 to 2.25) | <0.001 | – | – |
| CDAI | 1.08 (1.04 to 1.13) | <0.001 | 1.09 (1.05 to 1.14) | <0.001 | – | – |
| Axial spondyloarthritis, n=606 | ||||||
| Female gender | 1.66 (1.04 to 2.65) | 0.04 | – | – | 1.21 (0.71 to 2.05) | 0.48 |
| Age, years | 1.00 (0.98 to 1.01) | 0.64 | – | – | 1.00 (0.98 to 1.02) | 0.98 |
| Previous originator infliximab experienced (yes) | 0.55 (0.29 to 1.02 | 0.06 | 0.59 (0.31 to 1.12) | 0.10 | 0.60 (0.29 to 1.23) | 0.16 |
| Methotrexate use, yes | 0.65 (0.30 to 1.42) | 0.28 | 0.63 (0.29 to 1.39) | 0.25 | 0.66 (0.29 to 1.46) | 0.30 |
| Comorbidities ≥1 | 1.10 (0.65 to 1.84) | 0.72 | 1.11 (0.66 to 1.87) | 0.69 | 0.95 (0.54 to 1.69) | 0.86 |
| CRP, mg/L | 1.01 (0.99 to 1.04) | 0.31 | 1.01 (0.99 to 1.04) | 0.23 | 1.02 (0.99 to 1.05) | 0.28 |
| Patient global VAS, mm | 1.02 (1.01 to 1.02) | <0.001 | 1.01 (1.01 to 1.02) | <0.001 | 1.01 (1.01 to 1.02) | 0.001 |
| In ASDAS remission (yes) | 0.41 (0.22 to 0.77) | 0.005 | 0.42 (0.22 to 0.81) | 0.008 | – | – |
| ASDAS | 1.50 (1.20 to 1.87) | <0.001 | 1.48 (1.18 to 1.85) | <0.001 | – | – |
Bold values are those that were found to be significantly associated.
*Number of patients contributing to the analysis: rheumatoid arthritis: 571 (83%), psoriatic arthritis: 265 (84%), axial spondyloarthritis: 518 (85%).
ASDAS, Ankylosing Spondylitis Disease Activity Score; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; VAS, Visual Analogue Scale .